{
    "topic": "coronavirus",
    "source": "Yahoo! News",
    "bias": 0,
    "url": "https://finance.yahoo.com/news/coronavirus-update-hopes-build-over-gilead-drug-as-global-case-count-grows-161143044.html",
    "title": "Hopes build over Gilead drug as global case count grows",
    "date": "2020-04-29",
    "authors": "Anjalee Khemlani, Senior Reporter",
    "content": "An experimental antiviral drug to treat COVID-19 patients has fanned high expectations in the fight against the coronavirus pandemic , which has gained a decisive foothold in the United States and continues to spread around the world .\nGilead Sciences ( GILD ) acknowledged Wednesday that its drug , remdisivir , has seen positive results in both a company-sponsored and National Institute of Health-run study \u2014 with the federal regulators reportedly prepared to bestow emergency approval on the drug , according to The New York Times .\nThe treatment has been a frontrunner in the treatment race for the global coronavirus pandemic after it was first tested in China , which ended as enrollment numbers fell short . However , Gilead \u2019 s stock has mostly reaped the benefit of high expectations in a market desperate for good news , despite skepticism about what early test results meant for a broader deployment strategy .\n\u201c The study demonstrates the potential for some patients to be treated with a 5-day regimen , which could significantly expand the number of patients who could be treated with our current supply of remdesivir , \u201d Dr. Merdad Parsey , Gilead \u2019 s chief medical officer , said in a statement .\n\u201c This is particularly important in the setting of a pandemic , to help hospitals and healthcare workers treat more patients in urgent need of care , \u201d she added .\nThe news sparked a market rally , and amplified hopes for containing the global outbreak , which has now claimed more than 3.1 million lives and killed more than 218,000 . In the U.S. , more than 1 million are now infected , and killed more than 58,000 , as officials debate how to safely relax lockdowns that are crippling the economy .\nCalifornia is the latest state mulling a way to ease restrictions , and companies are calling employees back to the offices in June . Yet the Northeast remains a stronghold for growing cases and deaths , with New York and New Jersey seeing significant growth in infections despite falling hospitalization rates . Meanwhile , Massachusetts is also seeing increased rates of cases .\nTesting continues to be a major component of a reopening strategy , as the Centers for Disease Control eased restrictions on who can receive them . The U.S. has now tested more than 5.7 million individuals , with Rhode Island the top state in per capita testing , followed by New York and New Jersey .\nThe world 's largest economy accounts for about 1/3 of the COVID-19 cases worldwide , but has a lower per-capita death rate . More\nGilead \u2019 s study was a limited study of the effects of the drug on severe patients .\nThe study \u2019 s results show similar positive outcomes in severe patients who were on the drug for either five days or 10 days . The trial focused on patients who were not on ventilators , and were given the drug within 10 days after the onset of symptoms . At least 50 % of patients were discharged from the hospital .\nGilead said in its statement the results will still need to be peer-reviewed , but shows potential for the drug \u2019 s ability to treat patients who are not on ventilators .\nStill , the federal government appears to be moving quickly to capitalize on the results . The U.S. Food and Drug Administration is in talks with Gilead to help boost drug production and get the drug to patients as quickly as possible .\n\u201c As part of the FDA \u2019 s commitment to expediting the development and availability of potential COVID-19 treatments , the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible , as appropriate , \u201d the agency said in a statement .",
    "content_original": "An experimental antiviral drug to treat COVID-19 patients has fanned high expectations in the fight against the coronavirus pandemic, which has gained a decisive foothold in the United States and continues to spread around the world.\n\nGilead Sciences (GILD) acknowledged Wednesday that its drug, remdisivir, has seen positive results in both a company-sponsored and National Institute of Health-run study \u2014 with the federal regulators reportedly prepared to bestow emergency approval on the drug, according to The New York Times.\n\nThe treatment has been a frontrunner in the treatment race for the global coronavirus pandemic after it was first tested in China, which ended as enrollment numbers fell short. However, Gilead\u2019s stock has mostly reaped the benefit of high expectations in a market desperate for good news, despite skepticism about what early test results meant for a broader deployment strategy.\n\n\u201cThe study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir,\u201d Dr. Merdad Parsey, Gilead\u2019s chief medical officer, said in a statement.\n\n\u201cThis is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care,\u201d she added.\n\nThe news sparked a market rally, and amplified hopes for containing the global outbreak, which has now claimed more than 3.1 million lives and killed more than 218,000. In the U.S., more than 1 million are now infected, and killed more than 58,000, as officials debate how to safely relax lockdowns that are crippling the economy.\n\nCalifornia is the latest state mulling a way to ease restrictions, and companies are calling employees back to the offices in June. Yet the Northeast remains a stronghold for growing cases and deaths, with New York and New Jersey seeing significant growth in infections despite falling hospitalization rates. Meanwhile, Massachusetts is also seeing increased rates of cases.\n\nTesting continues to be a major component of a reopening strategy, as the Centers for Disease Control eased restrictions on who can receive them. The U.S. has now tested more than 5.7 million individuals, with Rhode Island the top state in per capita testing, followed by New York and New Jersey.\n\nThe world's largest economy accounts for about 1/3 of the COVID-19 cases worldwide, but has a lower per-capita death rate. More\n\n\n\nGilead\u2019s study shows promise\n\nGilead\u2019s study was a limited study of the effects of the drug on severe patients.\n\nThe study\u2019s results show similar positive outcomes in severe patients who were on the drug for either five days or 10 days. The trial focused on patients who were not on ventilators, and were given the drug within 10 days after the onset of symptoms. At least 50% of patients were discharged from the hospital.\n\nGilead said in its statement the results will still need to be peer-reviewed, but shows potential for the drug\u2019s ability to treat patients who are not on ventilators.\n\nStill, the federal government appears to be moving quickly to capitalize on the results. The U.S. Food and Drug Administration is in talks with Gilead to help boost drug production and get the drug to patients as quickly as possible.\n\n\u201cAs part of the FDA\u2019s commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate,\u201d the agency said in a statement.",
    "source_url": "www.finance.yahoo.com",
    "bias_text": "left",
    "ID": "zx3PDKxpah2mwfzC"
}